P2RY2 and cardiac hypertrophy: In summary, our results demonstrate that Compound 89, a 4(1H)-quinolinone derivative, is a potentially novel non-nucleotide allosteric P2Y2 agonist that inhibits the development of β-adrenergic agonist–induced cardiac hypertrophy through activation of NR4As.